Literature DB >> 8730115

Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study.

G Ferraccioli1, F Salaffi, S De Vita, L Casatta, E Bartoli.   

Abstract

OBJECTIVE: Steroids are the only treatment of polymyalgia rheumatica (PMR). We report the effects of methotrexate (MTX) plus prednisone versus prednisone alone in PMR.
METHODS: Twenty-four patients with recent onset PMR were studied in a randomized prospective study lasting one year. Patients were given MTX (MTX arm) 10 mg intramuscularly plus prednisone every week, or prednisone alone (Pred arm). After 6 months an attempt was made to stop prednisone, and to use the lowest possible dose over the next 6 months.
RESULTS: At the 12th month, all patients were in clinical remission, acute phase reactants were in the normal range in both arms of the study, 6 patients were no longer taking steroids in the MTX arm versus 0/12 in the Pred arm, and the amount of prednisone in the 2 groups was statistically different (1.84 versus 3.2 g; p < 0.0001). In addition, bone mineral density was significantly decreased in the Pred arm, but not in the MTX arm.
CONCLUSION: The MTX regimen allowed the use of much less prednisone over one year to obtain full control of PMR with no loss of efficacy. It also allowed sparing of bone in elderly patients at increased risk of osteoporotic fractures.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8730115

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  18 in total

Review 1.  Polymyalgia rheumatica/temporal arteritis: recent advances.

Authors:  Maria-Louise Barilla-LaBarca; Deborah J Lenschow; Richard D Brasington
Journal:  Curr Rheumatol Rep       Date:  2002-02       Impact factor: 4.592

Review 2.  Giant cell arteritis and polymyalgia rheumatica: pathophysiology and management.

Authors:  Miguel A Gonzalez-Gay; Carlos Garcia-Porrua; Jose A Miranda-Filloy; Javier Martin
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

3.  Effect of add-on methotrexate in polymyalgia rheumatica patients flaring on glucocorticoids tapering: a retrospective study.

Authors:  Diane Marsman; Thomas Bolhuis; Nathan den Broeder; Frank van den Hoogen; Alfons den Broeder; Aatke van der Maas
Journal:  Rheumatol Int       Date:  2021-01-23       Impact factor: 2.631

Review 4.  Polymyalgia rheumatica: strategies for efficient practice and quality assurance.

Authors:  Michael Schirmer; Christian Dejaco; Bhaskar Dasgupta; Eric L Matteson
Journal:  Rheumatol Int       Date:  2015-06-02       Impact factor: 2.631

Review 5.  [Diagnostics and treatment of polymyalgia rheumatica].

Authors:  C Dejaco; E L Matteson; F Buttgereit
Journal:  Z Rheumatol       Date:  2016-09       Impact factor: 1.372

Review 6.  Diagnosis, differential diagnosis and treatment of polymyalgia rheumatica.

Authors:  Thomas Nothnagl; Burkhard F Leeb
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 7.  Advances and challenges in the diagnosis and treatment of polymyalgia rheumatica.

Authors:  Tanaz A Kermani; Kenneth J Warrington
Journal:  Ther Adv Musculoskelet Dis       Date:  2014-02       Impact factor: 5.346

8.  Effects of leflunomide and methotrexate in rheumatoid arthritis detected by digital X-ray radiogrammetry and computer-aided joint space analysis.

Authors:  Alexander Pfeil; Julia Lippold; Thorsten Eidner; Gabriele Lehmann; Peter Oelzner; Diane M Renz; Andreas Hansch; Gunter Wolf; Gert Hein; Werner A Kaiser; Joachim Böttcher
Journal:  Rheumatol Int       Date:  2008-09-12       Impact factor: 2.631

9.  The effect of a nurse-led prednisolone tapering regimen in polymyalgia rheumatica: a retrospective cohort study.

Authors:  Christoffer Mørk; Mette Y Dam; Mikkel G Callsen; Kresten K Keller
Journal:  Rheumatol Int       Date:  2020-07-21       Impact factor: 2.631

10.  EULAR response criteria for polymyalgia rheumatica: results of an initiative of the European Collaborating Polymyalgia Rheumatica Group (subcommittee of ESCISIT).

Authors:  B F Leeb; H A Bird; G Nesher; I Andel; W Hueber; D Logar; C M Montecucco; J Rovensky; J Sautner; M Sonnenblick
Journal:  Ann Rheum Dis       Date:  2003-12       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.